Request Appointment
1275 York AvenueNew York, NY 10065
Overview of Dr. Rekhtman
Dr. Natasha Rekhtman is a pathologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 15 years. She is one of 158 doctors at Memorial Sloan Kettering Cancer Center who specialize in Pathology. She has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Cytopathology, 2007 - 2008
Johns Hopkins UniversityResidency, Pathology-Anatomic and Clinical, 2002 - 2006
Albert Einstein College of MedicineClass of 2002
Certifications & Licensure
NJ State Medical License 2024 - 2027
NY State Medical License 2007 - 2027
MD State Medical License 2006 - 2007
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Cytopathology
Publications & Presentations
PubMed
- Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms.Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, Zeynep C Tarcan, Courtney Porfido
Medrxiv. 2025-06-25 - 1 citationsDetection of SEZ6, a Therapeutic Target, in Medullary Thyroid Carcinoma.Bin Xu, Marina K Baine, Achim Jungbluth, Anas Alabkaa, Rene Serrette
The Journal of Clinical Endocrinology and Metabolism. 2025-06-17 - 3 citationsPan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.Christopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, Tom Zhang, Ryan Cheng
Cancer Discovery. 2025-06-03
Journal Articles
- PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung CancersG J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology
- Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Crit...J M Isbell, N Rekhtman, J D Wolchok, J E Chaft, Annals of Oncology
Press Mentions
MSK Researchers Discover New Type of SCLCSeptember 18th, 2024- Memorial Sloan Kettering Identifies New Lung CancerSeptember 12th, 2024
- New, Rare Type of Small Cell Lung Cancer IdentifiedSeptember 11th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
